Assembly Biosciences (NASDAQ:ASMB) Earns Buy Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Tuesday, MarketBeat reports. They presently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 66.61% from the company’s current price.

Other analysts have also issued research reports about the company. Guggenheim reissued a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 target price on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Stock Down 8.9%

Shares of NASDAQ ASMB opened at $30.01 on Tuesday. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71. The company has a market cap of $476.86 million, a P/E ratio of 29.42 and a beta of 1.10. The business’s 50 day moving average is $26.24 and its two-hundred day moving average is $27.40.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Sell-side analysts expect that Assembly Biosciences will post 1.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $26,122,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Assembly Biosciences during the fourth quarter valued at $22,625,000. Parkman Healthcare Partners LLC acquired a new position in shares of Assembly Biosciences during the third quarter valued at $6,425,000. Vanguard Group Inc. boosted its holdings in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after acquiring an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Assembly Biosciences in the fourth quarter worth about $5,476,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.